GlaxoSmithKline Pharmaceuticals Limited (BOM:500660)
India flag India · Delayed Price · Currency is INR
2,593.90
-73.05 (-2.74%)
At close: Feb 13, 2026

BOM:500660 Income Statement

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21
Operating Revenue
38,00737,49234,53732,51732,78029,256
38,00737,49234,53732,51732,78029,256
Revenue Growth (YoY)
2.59%8.56%6.21%-0.80%12.05%-9.27%
Cost of Revenue
13,82014,13913,55213,04113,78212,824
Gross Profit
24,18723,35420,98519,47618,99816,432
Selling, General & Admin
7,1767,0187,3587,0627,3976,858
Other Operating Expenses
4,0594,5244,5414,2723,9313,594
Operating Expenses
11,91512,21012,59511,99212,01011,236
Operating Income
12,27211,1438,3907,4846,9885,196
Interest Expense
-27.04-13.14-17.99-18.12-19.96-35.31
Interest & Investment Income
762.8762.8729.28698.55711.531,106
Currency Exchange Gain (Loss)
-22.66-22.66--99.07-51.36-
Other Non Operating Income (Expenses)
41.6---370.08
EBT Excluding Unusual Items
13,02711,8709,1018,0667,6666,266
Merger & Restructuring Charges
---1,633-113.7-200.84-2.4
Gain (Loss) on Sale of Investments
696.5696.5487.76307.795.92-
Gain (Loss) on Sale of Assets
-15.13-15.138.890.283.24-0.59
Asset Writedown
----2.61-2,090
Other Unusual Items
206.2246.92196.87104.02314366.44
Pretax Income
13,91512,5998,1628,3647,7904,540
Income Tax Expense
3,7053,3232,2622,2883,9831,667
Earnings From Continuing Operations
10,2109,2765,9006,0763,8082,873
Earnings From Discontinued Operations
---30.4513,140708.78
Net Income
10,2109,2765,9006,10716,9473,581
Net Income to Common
10,2109,2765,9006,10716,9473,581
Net Income Growth
18.83%57.23%-3.39%-63.97%373.19%284.26%
Shares Outstanding (Basic)
169169169169169169
Shares Outstanding (Diluted)
169169169169169169
EPS (Basic)
60.2654.7634.8336.05100.0421.14
EPS (Diluted)
60.2654.7634.8336.05100.0421.14
EPS Growth
18.84%57.23%-3.39%-63.97%373.19%284.26%
Free Cash Flow
-12,6695,5084,4027,7615,337
Free Cash Flow Per Share
-74.7832.5125.9845.8131.50
Dividend Per Share
42.00042.00032.00032.00030.00030.000
Dividend Growth
-31.25%-6.67%-50.00%
Gross Margin
63.64%62.29%60.76%59.89%57.96%56.17%
Operating Margin
32.29%29.72%24.29%23.02%21.32%17.76%
Profit Margin
26.86%24.74%17.08%18.78%51.70%12.24%
Free Cash Flow Margin
-33.79%15.95%13.54%23.68%18.24%
EBITDA
12,63211,5278,8057,8847,4285,733
EBITDA Margin
33.24%30.75%25.50%24.25%22.66%19.60%
D&A For EBITDA
359.73383.57415.36399.67439.6537.22
EBIT
12,27211,1438,3907,4846,9885,196
EBIT Margin
32.29%29.72%24.29%23.02%21.32%17.76%
Effective Tax Rate
26.63%26.38%27.72%27.35%51.12%36.72%
Revenue as Reported
39,50838,95135,76333,52433,53830,362
Advertising Expenses
-1,2021,0941,0911,277673.72
Source: S&P Global Market Intelligence. Standard template. Financial Sources.